Grail ($GRAL) NHS-Galleri Trial Results Case

• $GRAL investors filed a claim against Grail for overstating confidence in the NHS-Galleri trial while allegedly withholding risks that the trial might not show a statistically significant reduction in late-stage cancers.

• After Grail revealed the NHS-Galleri trial did not meet its primary endpoint, $GRAL fell 50.6% on February 20, 2026.

• $GRAL investors can join this case to be notified about potential recovery.

Case Details:

Between May 13, 2025 and February 19, 2026, Grail told investors that early NHS-Galleri results were positive and that the trial was designed to show whether Galleri could reduce late-stage cancers. Executives emphasized higher positive predictive value, consistent test performance, no serious safety concerns, and the importance of the upcoming final readout.

However, during this period, investors allege Grail knew or should have known the three-year follow-up period was too short to properly measure the trial’s key goal. Grail allegedly failed to disclose that the trial might not be able to show a statistically significant reduction in Stage III and IV cancers within the planned timeline; withheld first-round data may have shown weaker trends than investors understood, and the company’s confidence relied on alternative metrics that did not prove the trial would meet its main goal.

Then, on February 19, 2026, the company revealed the NHS-Galleri trial did not meet its primary endpoint of a statistically significant reduction in Stage III and IV cancers. $GRAL fell 50.6%, closing at $50.21.

Additional details followed during the same earnings call, including that Grail believed longer follow-up was needed and that, in hindsight, the trial likely should have allowed more time.

Based on these events, $GRAL investors filed a claim against Grail, alleging the company:

• It overstated confidence in the NHS-Galleri trial’s design.

• It highlighted positive test metrics while withholding risks about whether the trial could meet its main goal.

• It caused investors to reassess Grail when the trial missed its key endpoint.

Investors argue Grail misled the market about the NHS-Galleri trial’s likelihood of success, causing losses when the truth emerged.